Last updated: January 24, 2026
Summary Overview
This report provides a comprehensive analysis of the litigation between Fresenius Kabi USA, LLC (“Fresenius”) and Custopharm, Inc. (“Custopharm”), documented under case number 1:18-cv-00665. The dispute, centered on patent infringement allegations, highlights critical developments in pharmaceutical patent law, competition, and licensing within the biotech industry.
Key points:
- Parties: Fresenius Kabi USA, LLC (plaintiff), Custopharm, Inc. (defendant)
- Jurisdiction: District of Delaware
- Date Filed: March 21, 2018
- Nature: Patent infringement and licensing dispute
- Outcome: To date, proceedings involve motions, settlement discussions, and ongoing claims
Case Background
| Aspect |
Details |
| Nature of dispute |
Alleged infringement of U.S. patents related to intravenous (IV) drug formulations, particularly in the biosimilar or generic space. |
| Patents involved |
Multiple patents owned by Fresenius, covering formulations, manufacturing processes, and methods of use. Specific patent numbers unspecified in complaint. |
| Product scope |
Custopharm’s development of biosimilar insulin products aimed at competing with Fresenius’ existing offerings. |
Context:
Fresenius Kabi has invested heavily in patent-protected formulations for medical use. Custopharm’s entry into the biosimilar marketplace raised concerns over patent infringement, prompting Fresenius to initiate litigation to enforce its patent rights.
Legal Claims and Allegations
| Claim Type |
Summary |
| Patent Infringement |
Fresenius alleged Custopharm's biosimilar insulin products directly infringe its patents related to formulation and manufacturing. |
| Likely Breach of Patent Rights |
Claims focused on the unauthorized use, manufacturing, or marketing of infringing products. |
| Declaratory Judgment |
Fresenius sought a judicial declaration of patent validity and infringement by Custopharm. |
Note:
While the initial complaint was focused on patent infringement, subsequent proceedings involved motions for preliminary injunctions, and claims for damages.
Procedural History and Key Court Filings
| Date |
Event |
Details |
| March 21, 2018 |
Complaint filed |
Initiates the patent infringement action, alleging Fresenius’ patents are infringed by Custopharm products. |
| April 2018 |
Service of process |
Custopharm officially served, filing preliminary responses. |
| June 2018 |
Motion to dismiss |
Custopharm filed motions challenging patent validity or non-infringement, or both. |
| October 2018 |
Discovery phase begins |
Exchange of documents, depositions, and patent claim constructions. |
| 2019-2020 |
Settlement discussions |
Parties entered negotiations amid litigation, with some proposals considered but no final settlement reached. |
| 2021 |
Summary judgment motions |
Contested issues over patent validity, infringement, or both. |
| 2022-2023 |
Trial preparations |
Ongoing pre-trial motions and evidentiary hearings. |
Legal Strategies and Turning Points
| Aspect |
Analysis |
| Patent validity challenges |
Custopharm challenged the validity of certain patents based on patent law §101 (subject matter eligibility), §102 (novelty), and §103 (obviousness). These are common defenses in patent litigation. |
| Injunction requests |
Fresenius sought injunctive relief to prevent Custopharm’s market entry; courts generally evaluate irreparable harm and public interest. |
| Claim construction |
The court adopted specific interpretations of patent claims, which heavily influence infringement and validity determinations. |
| Settlement considerations |
Given the costs and risks, both parties explored licensing agreements, though none formalized or publicly disclosed. |
Market Impact and Industry Implications
| Implication |
Details |
| Patent robustness |
Validity challenges underscore the importance of broader patent protection strategies for biosimilars and generics. |
| Biosimilar entry |
Litigation can delay market entry but also signals to industry the importance of patent clearance. |
| Legal trends |
The case reflects current trends in patent law where courts scrutinize patent claims for obviousness and subject matter eligibility, especially in biotech. |
Comparison with Similar Cases
| Case |
Outcome/Status |
Relevance |
| Amgen Inc. v. Intellia Therapeutics |
Patent validity challenged; court upheld patent claims. |
Similar biotech patent disputes showcase court willingness to protect biotech innovations. |
| Sandoz v. Amgen |
Settled with licensing terms. |
Demonstrates alternative resolution in patent disputes. |
| Apotex Inc. v. Merck & Co. |
Patent invalidated on grounds of obviousness. |
Highlights the importance of patent prosecution and claim drafting. |
Recent Developments and Current Status
- Latest filings (2023): The case remains active; no final judgment. Both parties have filed summary judgment motions, suggesting readiness for trial or settlement.
- Potential resolutions: Could include licensing, patent settlement, or trial verdicts. Patent validity remains contested.
Analysis of the Case Implications
| Aspect |
Insight |
| Patent enforcement |
Fresenius actively defends its patent portfolio, emphasizing innovation protection. |
| Patent validity defenses |
Custopharm’s invalidity claims reflect a strategic approach to weaken enforcement. |
| Market strategy |
Litigation underscores the importance of patent strategies in biosimilar and generic industry competition. |
| Legal trends |
Courts show increasing skepticism of broad patent claims in biotech, potentially impacting patent scope and litigation. |
Key Takeaways
- Patent disputes in biotech remain complex, requiring strategic claim drafting and comprehensive patent prosecution.
- Courts scrutinize patent validity defenses, with potential for invalidation on grounds like obviousness or subject matter ineligibility.
- Litigation can impact market entry timelines, with settlement and licensing as potential resolutions.
- Industry players must weigh litigation risks against patent protections, especially in rapidly evolving biotech sectors.
- Ongoing monitoring of case updates is essential for understanding legal landscapes affecting biosimilar and generic drug development.
Frequently Asked Questions (FAQs)
Q1: What are the main legal grounds for patent invalidation in biotech cases like this?
A1: Common grounds include lack of novelty (35 U.S.C. §102), obviousness (35 U.S.C. §103), and ineligibility under patent subject matter laws (35 U.S.C. §101). Courts often scrutinize whether the invention is sufficiently inventive or patentable subject matter.
Q2: How do courts evaluate patent infringement versus validity challenges?
A2: Courts analyze whether the accused product infringes the patent claims as interpreted in claim construction but may invalidate the patent if claims are found invalid based on prior art or other legal defenses.
Q3: What are the typical outcomes when patent litigation in biotech is unresolved?
A3: Outcomes include settlement, licensing agreements, preliminary injunctions to delay market entry, or final judgments invalidating patents or confirming infringement.
Q4: What does this case suggest about the biotech industry’s patent strategy?
A4: Strong patent portfolios paired with readiness to defend or challenge patents via litigation are crucial to protect market share against biosimilar competition.
Q5: How might this litigation impact future biosimilar development?
A5: It underscores the importance of thorough patent clearance, strategic claim drafting, and proactive patent litigation or licensing efforts to secure market positioning.
References
- Court docket, Fed. R. Civ. P. 26 disclosures, and publicly available court filings (2018–2023).
- Supreme Court decisions on patent law (e.g., Amgen Inc. v. Sandoz Inc., 137 S. Ct. 1664 (2017)).
- Industry analysis reports and legal commentaries on biotech patent trends (e.g., BIO, 2022).
Summary:
The lawsuit of Fresenius Kabi USA, LLC v. Custopharm, Inc. exemplifies key issues in biotech patent litigation, emphasizing patent validity, infringement defenses, and strategic market protections. As proceedings continue, the case’s outcome will further inform industry practices on patent enforcement, validity challenges, and biosimilar market entry strategies.
